Clinical significance of IL-18 and IL-18-binding protein in bone marrow of patients with myelodysplastic syndrome
10.3760/cma.j.cn121090-20231009-00178
- VernacularTitle:IL-18和IL-18结合蛋白在骨髓增生异常综合征中的临床意义
- Author:
Ting WANG
1
;
Ningyuan RAN
;
Qiulin CHEN
;
Donglan LIU
;
Mengtong ZANG
;
Nianbin LI
;
Xin HE
;
Jing GUAN
;
Rong FU
;
Zonghong SHAO
Author Information
1. 天津医科大学总医院，天津 300052
- Keywords:
Myelodysplastic syndrome;
IL-18;
IL-18-binding protein;
Free IL-18
- From:
Chinese Journal of Hematology
2024;45(3):284-289
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the level and clinical significance of IL-18 and IL-18-binding protein (BP) in the bone marrow of patients with myelodysplastic syndrome (MDS) .Methods:A total of 43 newly diagnosed patients with MDS who were admitted to the Department of Hematology, Tianjin Medical University General Hospital, from July 2020 to February 2021 were randomly selected. The control group consisted of 14 patients with acute myeloid leukemia (AML) and 25 patients with iron-deficiency anemia (IDA). The levels of IL-18 and IL-18 BP in the bone marrow supernatant were measured, and their correlations with MDS severity, as well as the functionality of CD8 + T cells and natural killer cells, was analyzed. Results:The levels of IL-18, IL-18 BP, and free IL-18 (fIL-18) in the bone marrow supernatant of patients with MDS were higher than in the IDA group. The level of fIL-18 was linearly and negatively correlated with the MDS-International Prognostic Scoring System (IPSS) score. IL-18 receptor (IL-18Rα) expression on CD8 + T cells in the MDS group was lower than in the IDA group, and the levels of fIL-18 and IL-18Rα were positively correlated with CD8 + T-cell function in the MDS group. Conclusion:IL-18 BP antagonizes IL-18, leading to a decrease in fIL-18 in the bone marrow microenvironment of patients with MDS, affecting CD8 + T-cell function, which is closely related to MDS severity; therefore, it may become a new target for MDS treatment.
